Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Scrip Asks… Is The Biosimilar Cost-Saving Theory Sustainable?

Executive Summary

Scrip asks industry whether the promise of biosimilars producing substantial cost-savings is a sustainable model to help healthcare systems afford the next wave of expensive biologics. Drug developers and trade associations comment on the caveats still in play when it comes to biosimilars, cost-cutting and market access.

You may also be interested in...



Humira's Inevitable Decline: What's Waiting In The Wings?

There are 20 biosimilar adalimumab drugs in development – including one from Amgen that has already been approved but not yet launched. Biotechs and big pharma companies alike are lining up their candidates in preparation for when AbbVie's world-leading inflammation and immunology product Humira loses patent protection.

Biosimilar Firms Say Irish Price Deal Hinders Uptake, As Govt Plans New Policy Measures

The Irish health ministry is planning measures to boost the prescribing of biosimilar medicines, but companies marketing biosimilars say that the pricing agreement signed last year by the originator industry and the government has served to hinder uptake of their products.

Biologic Product Naming: US FDA Sticks With Suffixes ‘Devoid Of Meaning’

Final guidance adds new factors for biosimilar and innovative sponsors to consider in developing distinguishable suffixes for nonproprietary names but FDA is unswayed by calls for meaningful suffixes derived from license holder’s name; timing of retrospective application to previously approved products remains in question.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB001711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel